Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-25-Q-9102Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f4bb38e3b231424dadb1175bc4d5daad/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@mail.mil
    Julia Trang
    julia.n.trang.civ@health.mil
    Files
    Title
    Posted
    DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    The document outlines the process for the formulary placement of newly approved innovator drugs within the Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE Pharmacy Benefits Program, following the Final Rule published on July 27, 2015. The Pharmacy and Therapeutics (P&T) Committee is responsible for evaluating these drugs, classified under various chemical types, and has up to 120 days to recommend their tier placement on the uniform formulary. Newly approved drugs after August 26, 2015, will initially hold a pending status and will be reviewed quarterly for placement, considering clinical and cost-effectiveness. Prices must be available 30 days prior to meetings to avoid deferrals. Manufacturers can submit price concessions during specified solicitation windows, with drugs being categorized from Tier 1 to Tier 4/Not Covered based on the Committee's evaluations. Tier 3 designation generally limits these drugs' availability, except in cases where medical necessity is proven. The document emphasizes the structured approach to drug assessment, highlighting the Department of Defense’s efforts to ensure effective drug management in military healthcare.
    Price Appendix FAQ NAD.pdf
    The document outlines the procedures and requirements for submitting quotes for various drug-related categories within a government context. It provides detailed instructions for three main pricing frameworks: BPA (basic pricing agreements), ADP (non-FAMP and WAC discounts). Each section emphasizes the importance of filling in specified fields, indicated with yellow cells, and highlights how certain inputs auto-populate related fields, streamlining the data submission process. Key points include the necessity of understanding the P&T committee’s formulary decision-making process, the importance of correctly entering pricing information for National Drug Codes (NDCs), and the implications of submitting zero discounts, which will be flagged for the committee’s attention. Furthermore, it outlines guidelines for submitting more than the initial 10 NDCs by contacting designated points of contact. Overall, the document serves as a comprehensive guide for vendors seeking to participate in federal drug procurement, ensuring adherence to specific data entry protocols and emphasizing the significance of accurate pricing information in the context of governmental requests for proposals (RFPs). It aims to facilitate efficient bid submissions while maintaining compliance with federal standards and formularies.
    Price List - Itovebi - Oncological Agents - Breast Cancer.xlsx
    The document outlines the upcoming Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025, focusing on oncological agents specifically for breast cancer. It sets a deadline for quotes from manufacturers for newly approved drugs by December 19, 2024. The document details the approval process governed by the Department of Defense (DOD) Uniform Formulary, where drugs may be categorized as uniform or non-formulary based on specific pricing and usage criteria. Key elements include price per National Drug Code (NDC) and dosage forms, along with conditions for potential discounts through programs like TRICARE Retail Refund. The P&T Committee evaluates drugs for potential high-value status and may recommend exclusions from the TRICARE pharmacy benefit program. Essential procedural notes and conditions regarding prior authorization, step therapy, and manufacturers' responsibilities in submitting documentation are emphasized. The document serves as a guide for suppliers intending to engage with the Department of Defense’s formulary system, ensuring transparency and compliance with federal regulations for the procurement of oncological drugs.
    Price List - Miplyffa - Neurological Agents Miscellaneous - NA.xlsx
    The document pertains to the Department of Defense (DoD) Uniform Formulary for Neurological Agents Miscellaneous, presented for the P&T Committee meeting scheduled for February 5-6, 2025. It outlines the process for suppliers to submit quotes for newly approved drugs, with a submission deadline set for December 19, 2024. The document describes the requirement for submitted quotes to include specific details such as National Drug Code (NDC) number, drug name, strength, dosage form, and package size, while cautioning that lack of submission may highlight a company's intent not to participate. Additionally, it emphasizes that these agents may require prior authorization and may be eligible for special reimbursement methods aimed at encouraging the use of high-value products. The P&T Committee has the authority to recommend preferential treatment for certain non-generic pharmaceutical agents and can also identify drugs for exclusion from the TRICARE pharmacy benefit program. The overarching purpose of the document is to guide manufacturers in navigating the formulary submission process while ensuring compliance with the DoD's pharmaceutical procurement criteria, ultimately supporting the military healthcare system's drug formulary management.
    Price List - Opipza - Antipsychotic Agents - Atypical.xlsx
    The document outlines the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for February 5-6, 2025, focusing on antipsychotic agents, specifically atypical agents. It details a timeline for submitting quotes by December 19, 2024, for newly approved drugs, along with certain stipulations for the manufacturers. The proposal includes various scenarios emphasizing the need for price quotations for Uniform and Non-Formulary drugs, indicating that no quotes have been received thus far. The additional discount program appendices detail TRICARE retail refunds and requirements for submission, stressing the importance of confirming intent to quote. The document specifies that a prior authorization (PA) may be applicable for agents reviewed. The main goal is to facilitate contracts for pharmaceuticals while evaluating their reimbursement methods, promoting high-value products, and potentially altering their formulary status based on cost-sharing strategies. Overall, the document highlights the structured approach to enhancing DoD pharmacy services amidst regulatory standards aimed at ensuring effective healthcare support for its members.
    RFQ HT9402-25-Q-9102 NAD.pdf
    The Department of Defense (DoD) has issued a Request for Quotation (RFQ) related to the procurement of pharmaceutical agents for the Military Health System via the Defense Health Agency and the Pharmacy and Therapeutics Committee. This RFQ outlines the process by which pharmaceutical companies can submit price quotes for agents to be included in the Uniform Formulary (UF), which classifies drugs into tiers based on cost-effectiveness and clinical efficacy. Key components include instructions for quote submissions, government-provided data, and criteria for evaluating and awarding Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP). Companies must provide comprehensive pricing information, including National Drug Code (NDC) lists, and adhere to strict regulations regarding the inclusion of their pharmaceuticals in designated formularies. The document underscores the importance of compliance and transparency in pricing, with final approvals contingent upon evaluations by the DoD Pharmacy and Therapeutics Committee. The overarching goal is to ensure an effective and cost-efficient pharmacy benefits program for military health beneficiaries while facilitating competitive pricing from manufacturers.
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Doxycycline Hyclate Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. The procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with a focus on compliance with federal regulations and quality control measures. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by February 5, 2025, at 3:00 PM EST, and can contact Courtney Hunter-Stangler or Jason C. Wray for further information.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Famotidine
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Repaglinide
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    6515--Pharmacy Management System ScriptPro Brand name or Equal
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the procurement of a ScriptPro Pharmacy Management System or an equivalent solution, as outlined in the combined synopsis/solicitation RFQ 36C26225Q0148. This procurement aims to enhance pharmacy management capabilities across various Veterans Integrated Service Network (VISN) 22 medical facilities and clinics, ensuring high-quality healthcare service delivery through reliable technological advancements. Interested vendors are encouraged to participate, particularly small businesses, including those owned by veterans and women, with bids due by February 4, 2025, at 7:00 AM PST. For inquiries, potential bidders should contact Contracting Officer Anthony Dela Cruz at anthony.delacruz@va.gov or by phone at 562-766-2284.
    Tretinoin Cream
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Tretinoin Cream. The cream is used for various dermatological conditions and comes in different strengths (0.025%, 0.05%, and 0.1%) and tube sizes (20G and 45G). The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. It will establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. Interested parties should contact Ryan Ferry for more information. The projected solicitation date is February 2023.
    Pantoprazole DR Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    6505--770_Pharmaceuticals_VA CMOP National Office_36C77025Q0117 770-25-2-0182 - National CMOP T0224 TERBINAFINE HCL 1% CREAM
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified vendors to fulfill an emergency procurement of Terbinafine HCL 1% Cream for its Consolidated Mail Outpatient Pharmacy (CMOP) facilities across multiple locations. This acquisition, identified by solicitation number 36C77025Q0117, is set aside for small businesses and requires vendors to provide specific documentation, including a completed price schedule in Excel format and a state wholesale distributor license, to ensure compliance with the Drug Supply Chain Security Act. The timely delivery of these pharmaceuticals is crucial for maintaining a reliable supply for veterans, with a delivery timeframe of 10 days after receipt of order and shipments directed to seven designated CMOP locations. Interested vendors must submit their quotes by January 23, 2025, with an estimated award date of January 28, 2025; for further inquiries, contact Michael W. McAlhaney at Michael.McAlhaney@va.gov or (913) 684-0134.